Deutsches Krebsforschungszentrum

Ruprecht-karls-universitat Heidelberg

Basilea Pharmaceutica Ag

Friedrich-alexander-universitat Erlangen-nürnberg

Sinamira Ag

Daniel Gilbert

Michael Boutros

Corinna Koch

Florian Fuchs

Rajendra-Prasad Maskey

Sandra Steinbrink

Felix Bachmann

Heidi Alexandra Lane

Madlaina Breuleux

Xian Zhang

Oliver Friedrich

Walter Miedl

The present invention relates to a fast, simple and very sensitive method for the detection of bacteria, comprising the steps of providing one or more suspensions each comprising at least one species of labeled test bacteriophages which specifically bind to a bacterial species to be detected; adding a sample to be tested for the presence of at least one bacterial species to be detected to the one or more suspensions; filtering the reaction mixture; detecting bacteria-bacteriophages-complexes on the surface of the filter in the retentate, provided that at least one bacterial species to be detected is present, wherein the complexes consist of bacteria of the at least one bacterial species to be detected and test bacteriophages of the at least one species of test bacteriophages bound thereto; detecting unbound test bacteriophages in the filtrate; processor-aided processing of received detection signals and output of detection results.

Method and apparatus for the detection of bacteria

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I). 

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

Compounds of formula (IIc); wherein Xand Xindependently from each other are N or CRwherein Rmay be same or different; Y, Y, Yand Yindependently from each other are N or CRwherein Rmay be same or different and wherein up to 3 of the group Y, Y, Yand Ymay be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer. 

Chromene derivatives and their analogs as Wnt pathway antagonists

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula I wherein

Chromene derivatives and their analoga as Wnt pathway antagonists

The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer. 

Tricyclic pyrimidine derivatives as wnt antagonists

Growing community of inventors

Heidelberg, Germany

Daniel Gilbert